Literature DB >> 31911181

Glycosphingolipid metabolism and polycystic kidney disease.

Thomas A Natoli1, Vijay Modur2, Oxana Ibraghimov-Beskrovnaya3.   

Abstract

Sphingolipids and glycosphingolipids are classes of structurally and functionally important lipids that regulate multiple cellular processes, including membrane organization, proliferation, cell cycle regulation, apoptosis, transport, migration, and inflammatory signalling pathways. Imbalances in sphingolipid levels or subcellular localization result in dysregulated cellular processes and lead to the development and progression of multiple disorders, including polycystic kidney disease. This review will describe metabolic pathways of glycosphingolipids with a focus on the evidence linking glycosphingolipid mediated regulation of cell signalling, lipid microdomains, cilia, and polycystic kidney disease. We will discuss molecular mechanisms of glycosphingolipid dysregulation and their impact on cystogenesis. We will further highlight how modulation of sphingolipid metabolism can be translated into new approaches for the treatment of polycystic kidney disease and describe current clinical studies with glucosylceramide synthase inhibitors in Autosomal Dominant Polycystic Kidney Disease.
Copyright © 2020 The Author(s). Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 31911181     DOI: 10.1016/j.cellsig.2020.109526

Source DB:  PubMed          Journal:  Cell Signal        ISSN: 0898-6568            Impact factor:   4.315


  8 in total

1.  Metabolic reprogramming in a slowly developing orthologous model of polycystic kidney disease.

Authors:  Katharina Hopp; Emily K Kleczko; Berenice Y Gitomer; Michel Chonchol; Jost Klawitter; Uwe Christians; Jelena Klawitter
Journal:  Am J Physiol Renal Physiol       Date:  2022-01-17

2.  Modified Benzofuran-carboxamide Compounds as Glucosylceramide Synthase Inhibitors for Treating Diseases.

Authors:  Ram W Sabnis
Journal:  ACS Med Chem Lett       Date:  2022-05-12       Impact factor: 4.632

Review 3.  Therapeutic advances in ADPKD: the future awaits.

Authors:  Ivana Capuano; Pasquale Buonanno; Eleonora Riccio; Maria Amicone; Antonio Pisani
Journal:  J Nephrol       Date:  2021-05-19       Impact factor: 3.902

Review 4.  Renal Ciliopathies: Sorting Out Therapeutic Approaches for Nephronophthisis.

Authors:  Marijn F Stokman; Sophie Saunier; Alexandre Benmerah
Journal:  Front Cell Dev Biol       Date:  2021-05-13

5.  Novel cell lines derived from Chinese hamster kidney tissue.

Authors:  Yoshinori Kawabe; Masamichi Kamihira
Journal:  PLoS One       Date:  2022-03-31       Impact factor: 3.240

6.  The STAGED-PKD 2-Stage Adaptive Study With a Patient Enrichment Strategy and Treatment Effect Modeling for Improved Study Design Efficiency in Patients With ADPKD.

Authors:  Ronald D Perrone; Ali Hariri; Pascal Minini; Curie Ahn; Arlene B Chapman; Shigeo Horie; Bertrand Knebelmann; Michal Mrug; Albert C M Ong; York P C Pei; Vicente E Torres; Vijay Modur; Ronald T Gansevoort
Journal:  Kidney Med       Date:  2022-08-27

7.  Assessment of Target Engagement in a First-in-Human Trial with Sinbaglustat, an Iminosugar to Treat Lysosomal Storage Disorders.

Authors:  Martine Gehin; Meggane Melchior; Richard W D Welford; Patricia N Sidharta; Jasper Dingemanse
Journal:  Clin Transl Sci       Date:  2020-11-10       Impact factor: 4.689

Review 8.  Autosomal Dominant Polycystic Kidney Disease: From Pathophysiology of Cystogenesis to Advances in the Treatment.

Authors:  Jana Reiterová; Vladimír Tesař
Journal:  Int J Mol Sci       Date:  2022-03-19       Impact factor: 5.923

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.